Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q92838

UPID:
EDA_HUMAN

ALTERNATIVE NAMES:
Ectodermal dysplasia protein

ALTERNATIVE UPACC:
Q92838; A0AUZ2; A2A337; B7ZLU2; B7ZLU4; O75910; Q5JS00; Q5JUM7; Q9UP77; Q9Y6L0; Q9Y6L1; Q9Y6L2; Q9Y6L3; Q9Y6L4

BACKGROUND:
Ectodysplasin-A, identified for its role in signaling during the morphogenesis of ectodermal organs, specifically binds to receptors EDAR and EDA2R. This interaction is vital for the development of structures such as teeth and sweat glands, and it has implications in cell adhesion.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Ectodysplasin-A could open doors to potential therapeutic strategies for conditions like Ectodermal dysplasia 1, hypohidrotic, X-linked, and selective tooth agenesis, X-linked, 1. Its involvement in these diseases underscores the importance of targeted research for innovative treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.